Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic... Summary The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

Loading next page...
 
/lp/springer-journals/disease-control-with-brentuximab-vedotin-in-an-aged-patient-with-zwA1Lh0qQU

References (16)

Publisher
Springer Journals
Copyright
2017 Springer-Verlag Wien
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0325-5
Publisher site
See Article on Publisher Site

Abstract

Summary The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 1, 2017

There are no references for this article.